New drug duo aims to slow muscle decline in rare disease
Disease control
Recruiting now
This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can improve physical function in people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive…
Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC